Chronic Obstructive Pulmonary Disease (COPD)NCT07825636
Sensorimotor Function in COPD
An observational study of Chronic Obstructive Pulmonary Disease (COPD), run by Alanya Alaaddin Keykubat University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study was to investigate the level of sensorimotor function impairment according to disease stage in individuals with Chronic Obstructive Pulmonary Disease (COPD) and to determine whether functional differences exist between individuals with COPD and healthy controls. Read more about this study
- Who is it for?
- Ages 40 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease (COPD)
- How many people
- 95 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Oct 2024to 1 Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Individuals diagnosed with COPD or healthy controls between the age of 40-65 years.
Who may be able to join
- Individuals diagnosed with COPD,
- Aged 40-65 years, who volunteer to participate in the study,
- Who do not have additional musculoskeletal disorders, neurological or cardiorespiratory problems, or respiratory failure (not using long-term home oxygen therapy or non-invasive mechanical ventilation) will be included.
- Individuals aged 40-65 years who volunteer to participate in the study,
- Who do not have additional musculoskeletal disorders, neurological or cardiorespiratory problems,
- Who do not have communication problems will be included.
Who cannot join
- Individuals with uncorrected visual and hearing impairment,
- Individuals with a diagnosed serious chronic disease (neurological disease, cancer, chronic heart failure, etc.).
- Individuals with uncorrected visual and hearing impairment,
- A diagnosed serious chronic disease (neurological disease, cancer, chronic heart failure, etc.) will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Sensorimotor Function Impairment in Chronic Obstructive Pulmonary Disease
The aim of this study was to investigate the level of sensorimotor function impairment according to disease stage in individuals with Chronic Obstructive Pulmonary Disease (COPD) and to determine whether functional differences exist between individuals with COPD and healthy controls.
- Keywords
- Muscle dysfunction, Proprioception, Pain, Cognitive impairment
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Pain, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COPD Group | Not described | |
| Healthy Control | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Montreal Cognitive Assessment
Cognitive function was assessed using the Montreal Cognitive Assessment. The scale evaluates various cognitive domains, such as executive functions, visuospatial skills, attention, memory, language, abstraction, and orientation. The total score was calculated out of 30 points.
Measured: Enrollment
Pain Pressure Threshold and Tolerance
Pain threshold and pain tolerance were assessed using a digital pressure algometer (J-Tech Commander algometer, Preston Co., USA). Two measurements were taken from each site, and the mean value was used in the analysis.
Measured: Enrollment
Muscle Quality Index
Muscle quality was assessed using the Muscle Quality Index, calculated based on the duration of the 5-repetition sit-to-stand test, body weight, and leg length.
Measured: Enrollment
Secondary outcomes (1)
Lower Extremity Coordination Test
Lower extremity coordination was assessed using the Lower Extremity Coordination Test, performed as a heel-to-toe tapping task. The test is repeated three times over a 20-second period, and the best result is used in the analysis.
Measured: Enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2026
- Study start1 Oct 2024
- Primary completion1 May 2026
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Obstructive Pulmonary Disease (COPD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 95 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alanya Alaaddin Keykubat University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ayse Unal, Alanya Alaaddin Keykubat University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07825636
- Sponsor's protocol ID
- 2024/04
- Status last verified
- Sep 2026
- First submitted
- 6 Sep 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sensorimotor Function Impairment in Chronic Obstructive Pulmonary Disease
- ClinicalTrials.gov ID
- NCT07825636
- Acronym / sponsor ID
- 2024/04
- Keywords
- Muscle dysfunction, Proprioception, Pain, Cognitive impairment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 95 participants (actual)
- Lead sponsor
- Alanya Alaaddin Keykubat UniversityUniversity, hospital or other
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- 1 May 2026 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 17 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to investigate the level of sensorimotor function impairment according to disease stage in individuals with Chronic Obstructive Pulmonary Disease (COPD) and to determine whether functional differences exist between individuals with COPD and healthy controls.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| COPD Group | – | – |
| Healthy Control | – | – |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals diagnosed with COPD or healthy controls between the age of 40-65 years.
Key inclusion criteria (6 listed)
- Individuals diagnosed with COPD,
- Aged 40-65 years, who volunteer to participate in the study,
- Who do not have additional musculoskeletal disorders, neurological or cardiorespiratory problems, or respiratory failure (not using long-term home oxygen therapy or non-invasive mechanical ventilation) will be included.
- Individuals aged 40-65 years who volunteer to participate in the study,
- Who do not have additional musculoskeletal disorders, neurological or cardiorespiratory problems,
Key exclusion criteria (4 listed)
- Individuals with uncorrected visual and hearing impairment,
- Individuals with a diagnosed serious chronic disease (neurological disease, cancer, chronic heart failure, etc.).
- Individuals with uncorrected visual and hearing impairment,
- A diagnosed serious chronic disease (neurological disease, cancer, chronic heart failure, etc.) will be excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Montreal Cognitive Assessment
Time frame: Enrollment
Cognitive function was assessed using the Montreal Cognitive Assessment. The scale evaluates various cognitive domains, such as executive functions, visuospatial skills, attention, memory, language, abstraction, and orientation. The total score was calculated out of 30 points.
Pain Pressure Threshold and Tolerance
Time frame: Enrollment
Pain threshold and pain tolerance were assessed using a digital pressure algometer (J-Tech Commander algometer, Preston Co., USA). Two measurements were taken from each site, and the mean value was used in the analysis.
Muscle Quality Index
Time frame: Enrollment
Muscle quality was assessed using the Muscle Quality Index, calculated based on the duration of the 5-repetition sit-to-stand test, body weight, and leg length.
1 secondary outcome
Lower Extremity Coordination Test
Time frame: Enrollment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Chronic Obstructive Pulmonary Disease (COPD)
Active, not recruitingPhase 2
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
COPD
Not yet recruitingObservational study
Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)
Pulmonary Disease, Chronic Obstructive (COPD), Hypercapnia
RecruitingPhase 2
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 2
PRA-216 COPD Safety and Biomarker Study
Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease (COPD), run by Alanya Alaaddin Keykubat University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Montreal Cognitive Assessment (time frame: Enrollment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026; AzTrials last refreshed its copy on 29 Oct 2026.